A Phase 4 interventional study of pemetrexed in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 2 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-16.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 154th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 8 in phase 4, and was the 40th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 120th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 3 in phase 4, and was the 42nd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and toxicity of pemetrexed dosing that is tailored to individual patient tolerance in patients with advanced non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed
500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease. \*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade \>2; Skin Grade \>2; Serum bilirubin \>3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase \>10 x ULN; Other non-hematologic toxicities Grade \>2 (except nausea, vomiting).
Also known as: LY231514, Alimta
Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])
The objective response rate (ORR) was defined as the proportion of participants who achieved a best response of either complete response (CR) or partial response (PR) (responders) based on the RECIST criteria. ORR=(CR+PR)/Number of Participants. The RECIST define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments.
Time frame: baseline to measured progressive disease (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until documented disease progression, or up to 18 months after enrollment)
Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])
DCR was defined as the proportion of best overall response of CR, PR, and SD. DCR=(CR+PR+SD)/Number of participants. Response was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until documented disease progression, or up to 18 months after enrollment)
Overall Survival
Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last follow-up visit.
Time frame: baseline to date of death from any cause (includes post-treatment follow-up of up to 18 months post-Last Patient Entered Treatment)
Progression-Free Survival (PFS)
Time to PFS was defined as the time from the date of enrollment to the date of the first of the following events: objective disease progression or death due to any cause. Survival time frame includes post-treatment follow-up of up to 18 months post-Last Patient Entered Treatment. Patients were censored if their disease had not progressed, treatment was discontinued due to an undocumented progression or toxicity/other reason, onset of new anti-tumor therapy or otherwise experienced death/progression after more than one missed (assessment) visit.
Time frame: baseline to measured progressive disease or death from any cause (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until documented disease progression, or up to 18 months after enrollment)
Duration of Response
Duration of overall tumor response was measured from the time of first documentation of complete response or partial response (whichever status was first recorded) until the date of progression-free survival, with censoring defined as: disease had not progressed, treatment was discontinued due to undocumented progression or toxicity/other reason, onset of new anti-tumor therapy or otherwise experienced death/progression after more than one missed (assessment) visit.
Time frame: time of response to measured progressive disease or death from any cause (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until documented disease progression, or up to 18 months after enrollment)
Time to Treatment Failure
Time to treatment failure was define as the time from the date of enrollment to the date of the first of the following events: objective disease progression, death due to any cause, treatment discontinuation for undocumented progression, early treatment discontinuation for toxicity or other reason, or new anticancer treatment started. Time to treatment failure for participants who were still participating in the study without treatment failure at the time of analysis were treated as censored at the date of the last tumor assessment.
Time frame: baseline to early treatment discontinuation or measured progressive disease or death from any cause (assessments every 2 cycles during therapy and 6-8 weeks during post-therapy until documented disease progression, or up to 18 months after enrollment)
Time to Tumor Progression
Time to documented tumor progression was defined as the time from the date of enrollment to the first date of documented disease progression. Time to documented disease progression was censored at the date of death for participants who had not had documented disease progression. Otherwise, the censoring rules were the same as for Progression-Free Survival.
Time frame: baseline to measured progressive disease (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until documented disease progression, or up to 18 months after enrollment)
| Milestone | Pemetrexed |
|---|---|
| Started | 33 |
| Received at least one dose of study drug | 33 |
| Received escalated dose in cycle 2 | 25 |
| Completed | 15 |
| Not completed | 18 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death after 30-day post-therapy followup | 17 |
The objective response rate (ORR) was defined as the proportion of participants who achieved a best response of either complete response (CR) or partial response (PR) (responders) based on the RECIST criteria. ORR=(CR+PR)/Number of Participants. The RECIST define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments.
| proportion of responders | Pemetrexed |
|---|---|
| Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR]) | 0.182 (0.07 to 0.355) |
DCR was defined as the proportion of best overall response of CR, PR, and SD. DCR=(CR+PR+SD)/Number of participants. Response was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| proportion of participants | Pemetrexed |
|---|---|
| Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR]) | 0.545 (0.364 to 0.719) |
Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last follow-up visit.
| months | Pemetrexed |
|---|---|
| Overall Survival | 20.2 (0.7 to 32.0) |
Time to PFS was defined as the time from the date of enrollment to the date of the first of the following events: objective disease progression or death due to any cause. Survival time frame includes post-treatment follow-up of up to 18 months post-Last Patient Entered Treatment. Patients were censored if their disease had not progressed, treatment was discontinued due to an undocumented progression or toxicity/other reason, onset of new anti-tumor therapy or otherwise experienced death/progression after more than one missed (assessment) visit.
| months | Pemetrexed |
|---|---|
| Progression-Free Survival (PFS) | 6.9 (3.0 to 9.5) |
Duration of overall tumor response was measured from the time of first documentation of complete response or partial response (whichever status was first recorded) until the date of progression-free survival, with censoring defined as: disease had not progressed, treatment was discontinued due to undocumented progression or toxicity/other reason, onset of new anti-tumor therapy or otherwise experienced death/progression after more than one missed (assessment) visit.
| months | Pemetrexed |
|---|---|
| Duration of Response | 6.6 (1.6 to 9.7) |
Time to treatment failure was define as the time from the date of enrollment to the date of the first of the following events: objective disease progression, death due to any cause, treatment discontinuation for undocumented progression, early treatment discontinuation for toxicity or other reason, or new anticancer treatment started. Time to treatment failure for participants who were still participating in the study without treatment failure at the time of analysis were treated as censored at the date of the last tumor assessment.
| months | Pemetrexed |
|---|---|
| Time to Treatment Failure | 2.9 (1.7 to 4.9) |
Time to documented tumor progression was defined as the time from the date of enrollment to the first date of documented disease progression. Time to documented disease progression was censored at the date of death for participants who had not had documented disease progression. Otherwise, the censoring rules were the same as for Progression-Free Survival.
| months | Pemetrexed |
|---|---|
| Time to Tumor Progression | 6.9 (3.0 to 9.5) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 13/33 (39.4%) | 33/33 (100%) |
| Event | Pemetrexed |
|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/33 |
| AnaemiaBlood and lymphatic system disorders | 1/33 |
| LeukopeniaBlood and lymphatic system disorders | 1/33 |
| NeutropeniaBlood and lymphatic system disorders | 1/33 |
| Cardiac tamponadeCardiac disorders | 1/33 |
| Pericardial effusionCardiac disorders | 1/33 |
| PyrexiaGeneral disorders | 1/33 |
| CellulitisInfections and infestations | 1/33 |
| InfectionInfections and infestations | 1/33 |
| SepsisInfections and infestations | 1/33 |
| Event | Pemetrexed |
|---|---|
| FatigueGeneral disorders | 11/33 |
| PruritusSkin and subcutaneous tissue disorders | 11/33 |
| Alanine aminotransferase increasedInvestigations | 10/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/33 |
| VomitingGastrointestinal disorders | 9/33 |
| Chest painGeneral disorders | 9/33 |
| AnorexiaMetabolism and nutrition disorders | 9/33 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 9/33 |
| NauseaGastrointestinal disorders | 8/33 |
| PyrexiaGeneral disorders | 8/33 |
| Age Continuous(years) | Pemetrexed |
|---|---|
| Mean | 58.0 ± 11.27 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 13 |
| Male | 20 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| Taiwan | 33 |
| Disease Characteristic: Basis for Diagnosis(participants) | Pemetrexed |
|---|---|
| Histopathological | 17 |
| Cytological | 16 |
| Disease Characteristic: Disease Stage at Study Entry(participants) | Pemetrexed |
|---|---|
| Stage IIIB | 3 |
| Stage IV | 30 |
| Disease Characteristic: Eastern Cooperative Oncology Group Performance Status(participants) | Pemetrexed |
|---|---|
| 0 - Fully Active | 9 |
| 1 - Ambulatory, Restricted Strenuous Activity | 24 |
| Disease Characterstic: Pathological Diagnosis Code(participants) | Pemetrexed |
|---|---|
| Adenocarcinoma of Lung | 23 |
| Large Cell Carcinoma of Lung | 1 |
| Mixed Cell | 0 |
| Squamous Cell Carcinoma of Lung | 8 |
| Non-Small Cell Lung Carcinoma | 1 |
| Race/Ethnicity(participants) | Pemetrexed |
|---|---|
| East/Southeast Asian | 33 |
10 further baseline measures are reported on the registry.
The record gives a start of Nov 2006, a primary completion of Sep 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →